許多核苷(Nucleosides)的修飾物在抗病毒、抑制腫瘤細胞生長與核醫藥物上扮演相當重要的角色；目前已開發的藥物對於抗病毒有不錯之成效，但病毒的種類眾多與各式各樣新穎的病毒株出現，又加上面對環境的變遷，突變出更能適應的病毒株，使得原有藥性失效或降低。在本論文的研究裡以尿苷(Uridine)為起始物，主要合成出4’-α/β-aminomethyl uridine之相關核苷修飾化合物，來與市售各式各樣的酸基耦合形成醯胺鍵以建立起大量化分子庫。
合成路徑中，尿苷2',3',5'氫氧基先以TBDMSCl保護，接著HOAc將5'去掉保護，以EDC來將5'氫氧基氧化成醛基；置於NaOH鹼性條件下與甲醛反應，經NaBH4還原可製備出延伸出之4'碳氫氧支鏈尿苷。
後續將4'碳氫氧支鏈尿苷引入離去基；使用tosyl (TsO-)離去基無法成功的以N3-來置換，既使升高溫度(110℃)亦沒有反應；改以Triflate (TfO-)強離去基時，當接上一個當量的離去基，以LiN3行置換反應得到的化合物是經過環化路徑的2',4'-BNA (N-type)產物。由先前研究過文獻NMR光譜來比較，在C1',C2',C3'上個別的氫皆呈現單峰(偶合常數為零)。
接上兩個當量的TfO-離去基時，以LiN3行置換反應中，並無發生預期的環化現象，而N3-可將兩個離去基置換出；推測這可能是立障的關係，當存在兩個TfO-離去基時，結構上會造成立體障礙排擠使6'的離去基與2'矽保護基無法有效發生環化。之後以TBAF將TBDMS矽保護基移除，通入氫氣以Pd/C催化，使azido還原得到兩個氨基(amino)的尿苷類似物。
合成出的4',4'-bis-aminomethyl uridine，未來計劃與各式各樣的酸耦合，獲得大量化的醯氨尿苷類似物，以提供後續細胞活性試驗，期許高效率地篩選出具有潛力的新穎化合物。

Numerous nucleoside analogs play an important role in acting as anti-viral, anti-tumor and nuclear imaging agents. However, there are a variety of new viruses and various mutants appear, which may results in resistance or inefficiency of anti-viral activity. In this study, as the starting material, uridine was derivatized to afford 4'-α/β-aminomethyl uridine analogs followed by coupling with various acids for construction of libraries via amide-bond formation.
2',3',5'-hydroxyl groups of uridine were first protected with TBDMSCl, followed by restoring 5'-OH group with HOAc. After oxidation with EDC, the aldehyde could be produced. Treatment with
aqueous HCHO and NaOH and subsequent reduction with NaBH4, the 4'α-C-branched chain could be generated.
Attempt to introduce azido group by nucleophilic substitution of the tosyl group was unsuccessful even under 110 oC. Whereas triflate proved to be an excellent leaving group, only cyclized product 2',4'-BNA was obtained when one free hydroxy moieties were reacted with lithium azide. This was confirmed by comparing with the reported NMR spectra, which showed only singlet for all the three protons (coupling constant was zero) on C1', C2' and C3'.
Ditriflates could be prepared when two equivalents of triflic anhydride was used. Repeating the treatment with lithium azide, the desired azido groups could be introduced and no cyclized product was observed. The steric interference raised by the second trifluoromethan
-sulfonyl group was proposed to account for the unfavorable nucleophilic attack of 6'-OTf on 2'-TBDMS. Removal of TBDMS group was easily achieved using TBAF, which was followed by transformation of the azido groups to the diamino groups under reduction conditions of hydrogen gas and Pd/C.
As the target compound 4',4'-bis-aminomethyl uridine analog was in hand, further coupling with various carboxylic acids to provide the compound libraries through amide linkage are performable. Relevant biological assay studies to find out the potential compound are in progress.

[1] Robert J. Jones, Norbert Bischofberger Antiviral Res. 1995, 27,
1-17.
[2] L. Jordheim, C. M. Galmarini, and C. Dumontet Curr. Drug Targets
2003, 4, 443-460.
[3] Peter Wutzler, Rudolf Thust Antiviral Res. 2001, 49, 55-74.
[4] Rakesh Kumar Curr. Med. Chem. 2004, 11, 2749-2766.
[5] K Shah, A Jacobs, XO Breakefield1, R Weissleder Gene ther.
2004, 11, 1175-1187.
[6] Eric T. Kool, Juan C. Morales, and Kevin M. Guckian Angew.
Chem. –Int. Edit. 2000, 39, 990-1009.
[7] Shu-ichi Nakano, Yuuki Uotani, Shoji Nakashima, Yosuke Anno,
Masayuki ujii, and Naoki Sugimoto J. Am. Chem. Soc. 2003, 125,
8086-8087.
[8] Matt A. Peterson, BrDLEY l. Nilsson, Sanchita Sarker, Bogdan
Doboszewski, Weijian Zhang, and Morris J. Robins J. Org. Chem.
1999, 64, 8183-8192.
[9] Gian Maria Pacifici Early Hum. Dev. 2005, 81, 773-778.
[10]E. De Clercq Biochem. Pharmacol. 2004, 68, 2301-2315.
[11]Erik De Clercq J. Clin. Virol. 2004, 30, 115-133.
[12]Matthew D. Lynx, Alice T. Beutley, Edward E. Mckee Biochem.
Pharmacol. 2006, 71, 1342-1348.
[13] Erik De Clercq and Antonín Holý Nature 2005, 4, 928-940.
[14]B. Marples, O. Greco, M. C. Joiner, S.D. Scott Eur. J. Cancer 2002,
38, 231-239.
[15]Guang Xu, and Howard L. McLeod Clin. Cancer Res. 2001, 7,
3314-3324.
[16]Cheng Y. C., Grill S. P., Dutschman G. E., Nakayama K., Bastow K.
F. J. Biol. Chem. 1983, 258, 12460.
[17]Erik F. J. De Vries, Anne Rixt Buursma, Geke A.P. Hospers, Nanno
H. Mulder, and Willem Vaalburg Curr. Phar. Design 2002, 8, 1435
-1450.
[18] Moolten F. L. Cancer Res. 1986, 46 5276-5281.
[19] Naxin Wu and Mohammad M Ataai Curr. Opin. Biotechnol. 2000,
11, 205-208.
[20] Ralph Weissleder, Umar Mahmood Radiology 2001, 219, 316-333.
[21] K Shah, A Jacobs, XO Breakefield and R Weissleder Gene Ther.
2004, 11, 1175-1187.
[22] Juri Gelovani Tjuvajev, Mikhail Doubrovin, Timoyhy Akhurst,
Shangde Cai, Julius Balatoni, Mian M. Alauddin, Ronald Finn,
William Bornmann, Howard Thaler, Peter S. Conti, Ronald G.
Blasberg J. Nucl. Med. 2002, 43, 1072-1083.
[23]Seok Rye Choi, Zhi-Ping Zhuang, Ann-Marie Chacko, Paul D. Acton,
Juri Tjuvajev-Gelovani, Mikhai Doubrovin, David C. K. Chu, Hank F.
Kung Acad. Radiol. 2005, 12, 798-805.
[24]Ji-Quan Wang, Xiangshu Fei, Thomas A. Gardner, Gary D. Hutchuns,
and Qi-Huang Zheng Bioorg. Med. Chem. 2005, 13, 549–556.
[25]Michaela Grote, Steffi Noll, Bernhard Noll, Bernd Johannsen, and
Werner Kraus Can. J. Chem. 2004, 82, 513-523.
[26]Gareth Thomas Medicinal chemistry an introduction 2000 Wiley
Interscience.
[27]Chung-Yi Wu, Chuan-Fa Chang, Jenny Szu-Yu Chen, Chi-Huey
Wong, and Chun-Hung Lin Angew. Chem.- Int. Edit. 2003, 42,
4661-4664.
[28]Michael D. Best, Ashraf Brik, Eli Chapman, Lac V. Lee, Wei-Chieh
Cheng, and Chi-Huey Wong ChemBioChem 2004, 5, 811-819.
[29] Stephen Locarnini, William S. Mason J. Hepatol. 2006, 44, 422-431
[30] John D. Kriesel, Spotswood L. Spruance, Mark Prichard, Jacqueline
N. Parker and Earl R. Ken J. Infect. Dis. 2005, 192, 156-161.
[31] Makoto Nomura, Satoshi Shuto, Motohiro Tanaka, Takuma Sasaki,
Shuichi Mori, Shiro Shigeta, and Akira Matsuda J. Med. Chem. 1999,
42, 2901-2908.
[32] Satoru Kohgo, Kohei Yamada, Kenji Kitano, Yuko Iwai, Shinji
Sakata, Noriyuki Ashida, Hiroyuki Hayakawa, Daisuke Nameki,
Eiichi Kodama, Masao Matsuoka, Hiroaki Mitsuya, and Hiroshi
Ohrui Nucleoside Nucleotide Nucleic Acids 2004, 23, 671-690.
[33] Daniel Summerer and Andreas Marx Bioorg. Med. Chem. Lett. 2005,
15, 869-871.
[34] Maqbool A. Siddiqui, Stephen H. Hughes, Paul L. Boyer, Hiroaki
Mitsuya, Que N. Van, Clifford George, Stefan G. Sarafin anos, and
Victor E. Marquez J. Med. Chem. 2004, 47, 5041-5048.
[35] Satoshi Obika, Kem-ichiro Morioo, Daishu Nanbu, Yoshiyuki Hair,
Hiromi Itoh, and Takeshi Imanishi Tetrahedron 2002, 3039-3049.
[36] Ingrid Le Cle´zio, Heinz Gornitzka, Jean-Marc Escudier, and Alain
Vigroux J. Org. Chem. 2005, 70, 1620-1629.
[37] Henrik M. Pfundhellera, Torsten Bryldb, Carl E. Olsenc, and Jesper
Wengelb Helv. Chim. Acta 2000, 83, 128-151.
[38]Raymond D. Youssefyeh, Julien P. H. Verheyden, and John G. Moffatt
J. Org. Chem. 1979, 44, 1301-1309.
[39]Gordon H. Jones, Masao Taniguchi, Derek Tegg, and John G.
Moffatt J. Org. Chem. 1979, 44, 1309-1317.
[40]Mickael Montembault, Nathalie Bourgougnon, and Jacques Lebreton
Tetrahedron Lett. 2002, 43, 8091-8094.
[41]Helmut Vorbrüggen, Carmen Ruh-Pohlenz Handbook of Nucleoside
Synthesis 2001, Wiley Interscience.
[42]Theodora W. Greene, Peter G. M. Wuts Protective Groups on
Organic Synthesis 1999, 3th, Wiley Interscience.
[43]Erick M. Carreira, and J. Du Bois J. Am. Chem. Soc. 1995, 117,
8106-8125.
[44]S.Chandrasekhar, B. Nagendra Babu, N. Ramakrishna Reddy, and L.
Chandraiah Arkivoc 2005, 6, 40-47.
[45]Michael Meldgaard, Flemming Gundorph Hansen, and Jesper
Wengel J. Org. Chem. 2004, 69, 6310-6322.
[46]D.D. Perrin, and W. L. F. Armarego Purification of Laboratory
Chemicals 3th.
[47]Victor A. Timoshchuk, Richard I. Hogrefe, and Morteza M. Vaghefi
Nucleosides Nucleotides Nucleic Acids 2004, 23, 171-181.
[48]Hansjörg Streicher, Jöns Meisch, and Christoph Bohner Tetrahedron
2001, 57, 8851-8859.
[49]Yoshiyuki Hair, Satoshi Obika, Minako Sakaki, Ken-ichiro Morio,
Yuriko Yamagata, and Takeshi Imanishi Tetrahedron 2002, 58,
3051-3063.
[50] Nigel I. Howard, and Timothy D. H. Bugg Bioorg. Med. Chem. 2003, 11,
3083-3099.